These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 21752570)

  • 1. An experimental evaluation of patient decision aid design to communicate the effects of medications on the rate of progression of structural joint damage in rheumatoid arthritis.
    Martin RW; Brower ME; Geralds A; Gallagher PJ; Tellinghuisen DJ
    Patient Educ Couns; 2012 Mar; 86(3):329-34. PubMed ID: 21752570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis.
    Verburg RJ; Sont JK; Vliet Vlieland TP; Landewé RB; Boers M; Kievit J; van Laar JM
    J Rheumatol; 2001 Apr; 28(4):719-27. PubMed ID: 11327241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
    Nikolaisen C; Rekvig OP; Nossent HC
    Scand J Rheumatol; 2005; 34(4):269-76. PubMed ID: 16195159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice.
    Montag K; Gingold M; Boers A; Littlejohn G
    Intern Med J; 2011 Jun; 41(6):450-5. PubMed ID: 20403067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
    Weinblatt ME; Bathon JM; Kremer JM; Fleischmann RM; Schiff MH; Martin RW; Baumgartner SW; Park GS; Mancini EL; Genovese MC
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):373-82. PubMed ID: 20957659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician.
    Martin RW; Head AJ; René J; Swartz TJ; Fiechtner JJ; McIntosh BA; Holmes-Rovner M
    J Rheumatol; 2008 Apr; 35(4):618-24. PubMed ID: 18278840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.
    Le Loët X; Berthelot JM; Cantagrel A; Combe B; De Bandt M; Fautrel B; Flipo RM; Lioté F; Maillefert JF; Meyer O; Saraux A; Wendling D; Guillemin F
    Ann Rheum Dis; 2006 Jan; 65(1):45-50. PubMed ID: 15994280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Therapy in Rheumatoid Arthritis.
    Martin RW; Enck RD; Tellinghuisen DJ; Eggebeen AT; Birmingham JD; Head AJ
    Med Decis Making; 2017 Jul; 37(5):577-588. PubMed ID: 28590834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions.
    van der Helm-van Mil AH; le Cessie S; van Dongen H; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Rheum; 2007 Feb; 56(2):433-40. PubMed ID: 17265478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxycycline in the treatment of rheumatoid arthritis--a pilot study.
    Sreekanth VR; Handa R; Wali JP; Aggarwal P; Dwivedi SN
    J Assoc Physicians India; 2000 Aug; 48(8):804-7. PubMed ID: 11273473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
    Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.
    Gordon P; West J; Jones H; Gibson T
    J Rheumatol; 2001 Nov; 28(11):2409-15. PubMed ID: 11708411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.